Skin and wound research · Phase 1
Afamelanotide with phototherapy: vitiligo
NCT01430195 ↗ · Combined treatment
What was tested?
Afamelanotide plus narrowband UV-B phototherapy compared with phototherapy alone in adults with nonsegmental vitiligo. ↗
Registered primary question: Changes in pigmentation assessed with VASI and VETF measures across specified body regions over six months. ↗
What the reviewed report found
Journal year 2015 · Article summary reviewed 2026-09-15
The combination group had greater reported repigmentation at day 168. Erythema occurred in both groups; nausea and minor infections were reported in the combination group.↗
Keep in context: The report describes 55 randomized participants with skin phototypes III to VI; the registry lists 56 enrolled. This combination comparison does not isolate the effect of afamelanotide used alone. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 56 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Open label
- Design
- Parallel
- Eligible ages
- 18 Years; maximum not specified
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2013-03-22; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
Vitiligo: afamelanotide plus phototherapy
- Design in the report
- A randomized multicenter study compared afamelanotide plus narrowband UV-B with phototherapy alone.↗
- Participants in the report
- The study enrolled 55 adults with nonsegmental vitiligo and Fitzpatrick skin phototypes III–VI.↗
- Limitations
- The study does not isolate afamelanotide without phototherapy or establish results in all skin phototypes. PubMed links subsequent correspondence about the study.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV) ↗
Protocol identifier: CUV102. Sponsor: Clinuvel Pharmaceuticals Limited.
Retrieved 2026-09-20; SHA-256 85d4204d9f407ac31bd4a0b4cca8777d603d7f1308eaa12766344a7319bac4f9.
PMID 25230094
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 25230094. SHA-256 0e6795be99af1c93f3a3e2726fc8a17152661ca29e8dead110bff36feb856127.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 8fb8fb22056577dddd61a9f7dcdc0f316a95df3119b1d7e59a20cfa17d4c3eaf.